Portal de Periódicos da CAPES

Androgen deficiency and hormone‐replacement therapy

2005; Wiley; Volume: 96; Issue: 2 Linguagem: Inglês

10.1111/j.1464-410x.2005.05603.x

1464-410X

Andrea M. Isidori, Emanuela A. Greco, Antônio Aversa,

Pharmacology and Obesity Treatment

BJU InternationalVolume 96, Issue 2 p. 212-216 Androgen deficiency and hormone-replacement therapy Andrea M. Isidori, Andrea M. Isidori Cattedra di Andrologia andSearch for more papers by this authorEmanuela A. Greco, Emanuela A. Greco Cattedra di Andrologia andSearch for more papers by this authorAntonio Aversa, Corresponding Author Antonio Aversa Cattedra di Medicina Interna, Dipartimento Fisiopatologia Medica, Università'La Sapienza'di Roma, ItalyAntonio Aversa, Dipartimento di Fisiopatologia Medica, Università di Roma 'La Sapienza' Viale del Policlinico 155, 00161 Rome, Italy. e-mail: [email protected]Search for more papers by this author Andrea M. Isidori, Andrea M. Isidori Cattedra di Andrologia andSearch for more papers by this authorEmanuela A. Greco, Emanuela A. Greco Cattedra di Andrologia andSearch for more papers by this authorAntonio Aversa, Corresponding Author Antonio Aversa Cattedra di Medicina Interna, Dipartimento Fisiopatologia Medica, Università'La Sapienza'di Roma, ItalyAntonio Aversa, Dipartimento di Fisiopatologia Medica, Università di Roma 'La Sapienza' Viale del Policlinico 155, 00161 Rome, Italy. e-mail: [email protected]Search for more papers by this author First published: 07 July 2005 https://doi.org/10.1111/j.1464-410X.2005.05603.xCitations: 16Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab 1972; 34: 730– 5 2 Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991; 44: 671– 84 3 Morley JE, Kaiser FE, Perry HM III et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410– 3 4 Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997; 146: 609– 17 5 Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001; 86: 724– 31 6 Korenman SG, Morley JE, Mooradian AD et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990; 71: 963– 9 7 Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016– 25 8 Turner HE, Wass JA. Gonadal function in men with chronic illness. Clin Endocrinol (Oxf) 1997; 47: 379– 403 9 Morales A, Heaton JP, Carson CC III Andropause: a misnomer for a true clinical entity. J Urol 2000; 163: 705– 12 10 Feldman HA, Longcope C, Derby CA et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87: 589– 98 11 Spark RF, White RA, Connolly PB. Impotence is not always psychogenic. Newer insights into hypothalamic-pituitary-gonadal dysfunction. JAMA 1980; 243: 750– 5 12 Slag MF, Morley JE, Elson MK et al Impotence in medical clinic outpatients. JAMA 1983; 249: 1736– 40 13 Nickel JC, Morales A, Condra M, Fenemore J, Surridge DH. Endocrine dysfunction in impotence: incidence, significance and cost-effective screening. J Urol 1984; 132: 40– 3 14 Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 1995; 80: 3546– 52 15 Govier FE, McClure RD, Kramer-Levien D. Endocrine screening for sexual dysfunction using free testosterone determinations. J Urol 1996; 156: 405– 8 16 Araujo AB, O'donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920– 6 17 Gooren L. Androgen deficiency in the aging male: benefits and risks of androgen supplementation. J Steroid Biochem Mol Biol 2003; 85: 349– 55 18 Tan RS. Andropause. introducing the concept of 'relative hypogonadism' in aging males. Int J Impot Res 2002; 14: 319 19 Isidori AM, Giannetta E, Gianfrilli D et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005; in press 20 Isidori AM, Giannetta E, Greco EA et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in aging men: results in a meta-analysis. Clin Endocrinol (Oxf) 2005; in press 21 Isidori AM, Lenzi A. Risk factors for androgen decline in older males. lifestyle, metabolic disease and drug. J Endocrinol Invest 2005; 28 (suppl 3): 14– 23 22 Wespes E, Schulman CC. Male andropause. Myth, reality and treatment. Int J Impot Res 2002; 14: S93– S98 23 Tenover JL. Testosterone and the aging male. J Androl 1997; 18: 103– 6 24 Zirkin BR, Chen H. Regulation of Leydig cell steroidogenic function during aging. Biol Reprod 2000; 63: 977– 81 25 Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 2002; 87: 5410– 5 26 Isidori AM, Caprio M, Strollo F et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999; 84: 3673– 80 27 Isidori AM, Strollo F, More M et al. Leptin and aging. correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab 2000; 85: 1954– 62 28 Vermeulen A. Androgen replacement therapy in the aging male – a critical evaluation. J Clin Endocrinol Metab 2001; 86: 2380– 90 29 Algarte-Genin M, Cussenot O, Costa P. Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur Urol 2004; 46: 285– 94 30 Nieschlag E, Behre HM, Bouchard P et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 2004; 10: 409– 19 31 Wang C, Cunningham G, Dobs A et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085– 98 32 Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462– 8 33 Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis – immunomodulation and influence upon plaque development and stability. J Endocrinol 2003; 178: 373– 80 34 Grinspoon S, Corcoran C, Askari H et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129: 18– 26 35 Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab 2000; 85: 60– 5 36 Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482– 92 37 Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145: 2253– 63 38 Aversa A, Bruzziches R, Spera G. A rationale for the use of testosterone 'salvage' in treatment of men with erectile dysfunction failing phosphodiesterase inhibitors. The Endocrinologist 2005; 15: 99– 105 Citing Literature Volume96, Issue2August 2005Pages 212-216 ReferencesRelatedInformation